PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PLACENTAL EXTRACTS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 559 records · Page 31Linked to original sources
PubMed1992

Purification of a new anticoagulant protein, calphobindin III, from human placenta.

The Ca(2+)-phospholipid binding proteins in human placental tissue were investigated with the binding of a placental EDTA extract to liposomes composed of placental phospholipids. A new Ca(2+)-dependent phospholipid-binding protein different from calphobindin I (CPB I) and calphobindin II (CPB II) was isolated from the EDTA extract, and the purification procedure of this protein was established. The yield of the purified protein was about 1.2 mg from one placenta. The protein prolonged the clotting time of normal plasma when coagulation was induced by tissue factor and ellagic acid. This protein had an apparent molecular weight of 32,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions, and its isoelectric point was 5.8. Because of its ability to bind phospholipids in the presence of Ca2+, this protein was designated as calphobindin III (CPB III).

Annexins↗
PubMed2006

Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection.

A simple high-performance liquid chromatography (HPLC) method has been developed and validated for the simultaneous determination of abacavir and zidovudine (AZT) in rat plasma, amniotic fluid, fetal, and placental tissues. Extraction of abacavir, AZT, and the internal standard, azidouridine (AZDU) in amniotic fluid was carried out by protein precipitation. Extraction from plasma, fetal and placental homogenates was achieved by using a salting out technique. Chromatographic separation was performed using a C8 column (150 mm x 4.6 mm, 5 microm). The mobile phase consisted of 12% acetonitrile in 25 mM sodium phosphate buffer (adjusted to pH 7 with sodium hydroxide) for the fetus, placenta, plasma and amniotic fluid samples at a flow rate of 0.8 mL/min. The method was validated over the range from 0.05 to 50 microg/mL for both abacavir and AZT in the four biological matrices. The absolute recovery of abacavir ranged from 79 to 94%, while AZT recoveries ranged from 79 to 90% in the different biological matrices. The internal standard recovery ranged from 90 to 92%. Acceptable intra- and inter-day assay precision (<10% R.S.D.) and accuracy (<10% error) were observed over 0.05-50 microg/mL for all four matrices.

Animals↗
PubMed1980

Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments.

Monospecific antiserum to human placental alkaline phosphatase was purified by immunoabsorption and labeled with horseradish peroxidase. The binding of this labeled antibody to membrane fragments prepared from placental and tumor tissue was measured using agarose gel filtration to separate bound antibody. The antibody bound only to membrane fragments which contained placental phosphatase, and the amount bound varied in the order ascitic fluid membrane fragments greater than tumor extracts greater than placental extracts. Absorption of the antibody with crude placental membrane yielded a population of antibody which reacted with tumor tissue and pure placental enzyme, but only slightly with placental membranes. These results are interpreted to suggest that some antigenic sites are exposed in tumor tissue membranes which are not in placental membranes.

Adenocarcinoma↗